Skip to content

Kasabach - Merritt phenomenon optimization treatment clinical research program

Kasabach - Merritt phenomenon optimization treatment clinical research program

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900023865
Enrollment
Unknown
Registered
2019-06-15
Start date
2019-06-01
Completion date
Unknown
Last updated
2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kaposi form hemangio endothelioma

Interventions

1:Corticosteroid
2:rapamycin
3:hormone in combination with propranolol
4:rapamycin in combination with propranolol
5:hormone in combination with vincristine
6:Rapamycin in combination with hormones

Sponsors

Beijing Children's Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) children with clinical and pathological diagnosis of kaposi-like vascular endothelioma; (2) stable vital signs; (3) be able to receive treatment and follow up according to regulations; (4) parents or legal guardians voluntarily participate and sign the informed consent.

Exclusion criteria

Exclusion criteria: Any of the following can be excluded: (1) bronchial asthma and family history; (2) cardiogenic shock; (3) heart block (II to III degree atrioventricular block). (4) severe heart failure; (5) sinus bradycardia; (6) allergy to glucocorticoid, vincristine and rapamycin; (7) congestive heart failure; (8) diabetes; (9) emphysema or non-allergic bronchitis; (10) liver dysfunction; (11) hypothyroidism; (12) raynaud's syndrome or other peripheral vascular diseases; (13) renal dysfunction; (14) autoimmune diseases; (15) immunodeficiency diseases; (16) infectious diseases; (17) leukocytosis; (18) patients who are participating in another clinical study; (19) the researcher judged that the compliance of the children was poor and the study could not be completed as required.

Design outcomes

Primary

MeasureTime frame
platelet;fibrinogen;Size of the tumor;depth of the tumor;Blood supply of tumors;

Countries

China

Contacts

Public ContactLin Ma

Beijing Children's Hospital Affiliated to Capital Medical University

bch_maleen@aliyun.com+86 18610198779

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026